Placeholder Banner

NORD Urges Congress: Don’t Cut Orphan Drug Tax Credit

July 30, 2013
This week, the National Organization of Rare Disorders (NORD) and more than 70 patient organizations sent a letter to key members of Congress in support of maintaining the Orphan Drug Tax Credit.

Representing millions of American men, women and children suffering from rare diseases, the organizations voice strong support for the Orphan Drug Tax Credit (ODTC) and urge Congress to keep this critical tax credit in place as tax reform proposals are developed.

According to Marlene E. Haffner, MD, MPH, former Director of the FDA Office of Orphan Products Development: “Tax credits are an integral part of the Orphan Drug Program and are a lifeline to small and medium-sized firms as they are developing and growing their business and their products to treat rare diseases. The tax credits are a very small portion of tax revenue, but a very large incentive for the development of products for the treatment of rare diseases, many of which are life-threatening; 50% of those affected by these diseases are children.”

Access the full letter here.